Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Friday, January 3, 2025 1 min read
Key Takeaway: Madrigal Pharmaceuticals, Inc. has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 15, 2025. The presentation, which will be accessible via webcast, is expected to highlight the company's innovative approaches to treating metabolic dysfunction-associated steatohepatitis (MASH). Madrigal's medication, Rezdiffra, is specifically designed to tackle the critical aspects of this liver disease, showcasing the company's commitment to addressing significant medical needs in this area.
Market Sentiment Analysis
POSITIVE FACTORS
Madrigal Pharmaceuticals will present at a significant healthcare conference.
The company's focus on MASH addresses a high unmet medical need.
Their medication, Rezdiffra, targets key underlying causes of liver disease.
Full Press Release Details
CONSHOHOCKEN, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PT. The presentation will be webcast live and can be accessed here or by visiting Madrigal’s Investor Relations Site, Events and Presentations.
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. For more information, visit www.madrigalpharma.com.